1. Background
2. Objectives
3. Methods
3.1. Patients and Samples
3.2. Anti-microbial Susceptibility Testing and Multi-drug Resistant Gram-negative Bacteria Characterization
3.3. COVID-19 Detection
3.4. Statistical Analysis
4. Results
4.1. Patients
| Variables | Frequency (%), (N = 255) |
|---|---|
| Gender | |
| Male | 147 (75.64) |
| Female | 108 (42.35) |
| Age, y | |
| ≤5 | 175 (68.62) |
| 6 - 10 | 55 (21.56) |
| ≥11 | 25 (9.8) |
| Ward | |
| PICU a | 96 (37.64) |
| Oncology | 72 (28.23) |
| BMT b | 25 (9.8) |
| Gastro-intestinal | 14 (5.5) |
| Infectious disease | 14 (5.5) |
| Surgery | 10 (3.9) |
| Nephrology | 9 (3.5) |
| Others | 15 (5.8) |
| COVID-19 | |
| Yes | 64 (25) |
| No | 191 (75) |
| Death | 10 (9.8) |
| Yes | 65 (25.5) |
| No | 190 (74.5) |
a bone marrow transplantation
b pediatric intensive care unit
4.2. The Frequency of GNB Isolated from the Blood of Children
4.3. The Resistant Profile of Gram-negative Bacteria and Frequency of Multi-drug Resistant Strains
| Antibiotics | Escherichia spp. (N = 9) | Klebsiella spp. (N = 88) | Enterobacter spp. (N = 12) | Citrobacter spp. (N = 1) | Yersinia spp. (N = 1) | Acinetobacter spp. (N = 55) | Stenotrophomonas (N = 3) | Pseudomonasspp. (N = 86) |
|---|---|---|---|---|---|---|---|---|
| GM (10 µg) | 7 (77.77) | 80 (90.9) | 11 (91.6) | 0 | 0 | 36 (65.45) | 1 (33.33) | 48 (55.81) |
| TOB (10 µg) | 8 (88.88) | 81 (92.04) | 11 (91.6) | 1 (100) | 0 | 49 (89.09) | 3 (100) | 50 (58.13) |
| AN (30 µg) | 8 (88.88) | 71 (80.6) | 8 (66.66) | 1 (100) | 0 | 29 (52.72) | 3 (100) | 35 (40.69) |
| CIP (5 µg) | 5 (55.55) | 57 (62.5) | 7 (58.33) | 0 | 1 (100) | 14 (25.45) | 2 (66.66) | 21 (24.4) |
| LVX (5 µg) | 6 (66.66) | 68 (77.27) | 10 (83.33) | 1 (100) | 0 | 19 (34.54) | 3 (100) | 21 (24.4) |
| PIP (30 µg) | 6 (66.66) | 81 (92.04) | 11 (91.6) | 1 (100) | 1 (100) | 49 (89.9) | 3 (100) | 59 (68.6) |
| CAZ (30 µg) | 8 (88.88) | 81 (92.04) | 11 (91.6) | 1 (100) | 1 (100) | 50 (90.9) | 3 (100) | 67 (77.9) |
| PTAZ (110 µg) | 5 (55.55) | 80 (90.9) | 11 (91.6) | 1 (100) | 1 (100) | 49 (89.9) | 3 (100) | 58 (67.44) |
| CFM (30 µg) | 5 (55.55) | 80 (90.9) | 11 (91.6) | 1 (100) | 0 | 47 (85.45) | 3 (100) | 56 (65.11) |
| AZT (30 µg) | 5 (55.55) | 71 (80.6) | 11 (91.6) | 1 (100) | 0 | 48 (87.27) | 3 (100) | 55 (63.95) |
| IMP (10 µg) | 4 (44.44) | 66 (75) | 11 (91.6) | 1 (100) | 1 (100) | 46 (83.63) | 2 (66.66) | 57 (66.27) |
| MEM (10 µg) | 7 (77.77) | 80 (90.9) | 9 (75) | 0 | 1 (100) | 48 (87.27) | 3 (100) | 59 (68.6) |
| SXT (2.5 µg) | 8 (88.88) | 75 (85.22) | 11 (91.6) | 0 | 0 | 31 (56.36) | 2 (66.66) | _ |
| CTX (30 µg) | 9 (100) | 79 (89.77) | 11 (91.6) | 1 (100) | 0 | 49 (89.9) | 3 (100) | _ |
| AMP (10 µg) | 7 (77.77) | 83 (94.31) | 11 (91.6) | 1 (100) | 1 (100) | 50 (90.9) | 3 (100) | _ |
| APS (20 µg) | 9 (100) | 83 (94.31) | 10 (83.33) | 1 (100) | 1 (100) | 49 (89.9) | 3 (100) | _ |
| DOX (30 µg) | _ | _ | _ | _ | _ | 44 (80) | 3 (100) | _ |
| DOR (10 µg) | 9 (100) | 82 (93.18) | 11 (91.6) | 1 (100) | 1 (100) | 44 (80) | 3 (100) | _ |
| TET (30 µg) | 9 (100) | 79 (89.77) | 11 (91.6) | 1 (100) | 0 | 47 (85.45) | 3 (100) | _ |
| CN (30 µg) | 8 (88.88) | 73 (82.95) | 11 (91.6) | 1 (100) | 0 | 47 (85.45) | 3 (100) | _ |
| CXM (30 µg) | 9 (100) | 82 (93.18) | 11 (91.6) | 1 (100) | 1 (100) | 47 (85.45) | 3 (100) | _ |
| CFX (30 µg) | _ | _ | _ | _ | _ | 47 (85.45) | 3 (100) | _ |
Abbreviations: GM, gentamycin (10 µg); TOB, tobramycin (10 µg); AN, amikacin (30 µg); CIP, ciprofloxacin (5 µg); LVX, levofloxacin (5 µg); PIP, piperacillin (30 µg); CAZ, ceftazidime (30 µg); PTAZ, piperacillin-tazobactam (110 µg); CFM, cefepime (30 µg); AZT, aztreonam (30 µg); IMP, imipenem (10 µg); MEM, meropenem (10 µg); SXT, trimethoprim-sulfamethoxazole (2,5 µg); CTX, cefotaxime (30 µg); AMP, ampicillin (10 µg); APS, ampicillin-sulbactam (20 µg); DOX, doxycycline (30 µg); DOR, doripenem (10 µg); TET, tetracycline (30 µg); CN, chloramphenicol (30 µg); CXM, cefuroxime (30 µg); and CFX, cephalexin (30 µg).
a Values are expressed as No. (%).
4.4. MDR Strains and COVID-19 in Children
| GNB Strains | Frequency of MDR in Blood Samples | COVID-19 Test of the Patients with MDR Bacteremia | P-Value |
|---|---|---|---|
| Pseudomonas spp. | 77.9% (67/86) | 19.4% (13/67) | 0.002 |
| Acinetobacter spp. | 89.09 (49/55) | 12.24% (6/49) | |
| K. pneumonia | 94.33% (83/88) | 36.14% (30/83) | |
| E.coli | 88.88% (8/9) | 62.5% (5/8) | |
| Enterobacter genus | 83.33% (10/12) | 40% (4/10) | |
| Yersinia spp. | 0 | 0 | |
| Citrobacter spp. | 100 (1/1) | 0 | |
| Stenotrophomonas spp. | 100% (3/3) | 66.66% (2/3) |